Waters XenoTech has begun offering new metabolite profiling services. This has been possible with the Synapt High Definition Mass Spectrometry (HDMS) System.

In fact the Synapt HDMS System is the centerpiece of its metabolite profiling efforts and allows XenoTech to offer one-of-a-kind services to companies that are investigating promising new drug candidates.

Integrated with a Waters Acquity UltraPerformance Liquid Chromatograph, the Synapt HDMS System will provide XenoTech's scientific consultants with in vitro drug metabolism study data to support its clients' drug discovery decision-making process, offering them insights into the viability of potential drug candidates prior to their introduction into clinical trials.

"We have built a high degree of quality into XenoTech's products and in vitro services," states Andrew Parkinson, CEO & CSO, XenoTech. "We enjoy a good reputation for drug metabolism research and for our consultative approach to contract services. Our customers know that they can expect the best from us, and in turn, we expect the best from the instrumentation that we use to investigate their compounds," he said.

Customers are faced with the need to collect more information on their developmental drugs with limited budgets and reduced staff. "As a provider of contract services, we must produce the most meaningful and reliable data as quickly and efficiently as possible using small amounts of costly test compounds, and offer flexibility in our study designs to achieve cost savings and provide value for money. The Waters Synapt HDMS System was a perfect fit for both our scientific expectations and our operational requirements," Parkinson said.

Metabolic profiling is an important and growing area of expertise for XenoTech. Its unique system of in vitro metabolite profiling can alleviate the need for expensive and time-consuming pre-clinical animal studies.